PureTech Health (PTCHF) FDA Approvals

PureTech Health logo
$1.65 0.00 (0.00%)
As of 11/13/2026

PureTech Health's Drug in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by PureTech Health (PTCHF). Over the past two years, PureTech Health has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as SPT-320. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

SPT-320 FDA Regulatory Events

SPT-320 is a drug developed by PureTech Health for the following indication: to treat generalized anxiety disorder. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

PureTech Health FDA Events - Frequently Asked Questions

As of now, PureTech Health (PTCHF) has not received any FDA approvals for its therapy in the last two years.

In the past two years, PureTech Health (PTCHF) has reported FDA regulatory activity for SPT-320.

The most recent FDA-related event for PureTech Health occurred on October 9, 2026, involving SPT-320. The update was categorized as "Presentation," with the company reporting: "Seaport Therapeutics, Inc announced the presentation of Phase 1 clinical data for GlyphAgo™ (SPT-320 or Glyph Agomelatine) at the 39th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 10-13, 2026, in Munich, Germany."

Currently, PureTech Health has one therapy (SPT-320) targeting the following condition: to treat generalized anxiety disorder.

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for OTCMKTS:PTCHF last updated on 10/9/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners